Klingemann H - Search Results

1

Immunotherapy for Dogs: Still Running Behind Humans.

Klingemann H. Klingemann H. Front Immunol. 2021 Aug 5;12:665784. doi: 10.3389/fimmu.2021.665784. eCollection 2021. Front Immunol. 2021. PMID: 34421888 Free PMC article. Review.

2

Immunotherapy for Dogs: Running Behind Humans.

Klingemann H. Klingemann H. Front Immunol. 2018 Feb 5;9:133. doi: 10.3389/fimmu.2018.00133. eCollection 2018. Front Immunol. 2018. PMID: 29459862 Free PMC article. Review.

3

Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells.

Klingemann H, Boissel L, Toneguzzo F. Klingemann H, et al. Front Immunol. 2016 Mar 14;7:91. doi: 10.3389/fimmu.2016.00091. eCollection 2016. Front Immunol. 2016. PMID: 27014270 Free PMC article. Review.

4

NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy.

Suck G, Odendahl M, Nowakowska P, Seidl C, Wels WS, Klingemann HG, Tonn T. Suck G, et al. Cancer Immunol Immunother. 2016 Apr;65(4):485-92. doi: 10.1007/s00262-015-1761-x. Epub 2015 Nov 11. Cancer Immunol Immunother. 2016. PMID: 26559813 Free PMC article. Review.

5

CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.

Schomer NT, Jiang ZK, Lloyd MI, Klingemann H, Boissel L. Schomer NT, et al. Among authors: klingemann h. Cytotherapy. 2022 Aug;24(8):827-834. doi: 10.1016/j.jcyt.2022.02.006. Epub 2022 Apr 8. Cytotherapy. 2022. PMID: 35400595

6

Cellular Immunotherapy of Canine Cancer.

Addissie S, Klingemann H. Addissie S, et al. Among authors: klingemann h. Vet Sci. 2018 Dec 6;5(4):100. doi: 10.3390/vetsci5040100. Vet Sci. 2018. PMID: 30563208 Free PMC article. Review.

7

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.

Oelsner S, Friede ME, Zhang C, Wagner J, Badura S, Bader P, Ullrich E, Ottmann OG, Klingemann H, Tonn T, Wels WS. Oelsner S, et al. Among authors: klingemann h. Cytotherapy. 2017 Feb;19(2):235-249. doi: 10.1016/j.jcyt.2016.10.009. Epub 2016 Nov 22. Cytotherapy. 2017. PMID: 27887866 Free article.

8

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting.

Eitler J, Wotschel N, Miller N, Boissel L, Klingemann HG, Wels W, Tonn T. Eitler J, et al. Among authors: klingemann hg. J Immunother Cancer. 2021 Jan;9(1):e001334. doi: 10.1136/jitc-2020-001334. J Immunother Cancer. 2021. PMID: 33468562 Free PMC article.

9

Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.

Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H. Boissel L, et al. Among authors: klingemann h. Biol Blood Marrow Transplant. 2008 Sep;14(9):1031-1038. doi: 10.1016/j.bbmt.2008.06.016. Biol Blood Marrow Transplant. 2008. PMID: 18721766 Free article.

10

Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation.

Friedman R, Betancur M, Boissel L, Tuncer H, Cetrulo C, Klingemann H. Friedman R, et al. Among authors: klingemann h. Biol Blood Marrow Transplant. 2007 Dec;13(12):1477-86. doi: 10.1016/j.bbmt.2007.08.048. Biol Blood Marrow Transplant. 2007. PMID: 18022578 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

229 results

Search Page